$1.15 Billion is the total value of Palo Alto Investors LP's 33 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 5.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $170,826,000 | +3.6% | 2,061,373 | -3.7% | 14.89% | +16.7% |
| UTHR | Sell | UNITED THERAPEUTICS CORP | $149,586,000 | +27.7% | 634,806 | -2.8% | 13.04% | +43.9% |
| ABMD | ABIOMED INC | $122,368,000 | -25.3% | 494,397 | 0.0% | 10.67% | -15.8% | |
| INSM | Sell | INSMED INC | $115,173,000 | -16.7% | 5,840,398 | -0.7% | 10.04% | -6.0% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $105,765,000 | +12.8% | 9,847,774 | -0.6% | 9.22% | +27.1% |
| STAA | Sell | STAAR SURGICAL CO | $78,489,000 | -13.6% | 1,106,567 | -2.7% | 6.84% | -2.6% |
| BIIB | BIOGEN INC | $73,618,000 | -3.2% | 360,981 | 0.0% | 6.42% | +9.2% | |
| RVNC | Sell | REVANCE THERAPEUTICS INC | $60,878,000 | -29.3% | 4,405,039 | -0.2% | 5.31% | -20.3% |
| PRTA | PROTHENA CORP PLC | $45,652,000 | -25.8% | 1,681,477 | 0.0% | 3.98% | -16.3% | |
| SAGE | Sell | SAGE THERAPEUTICS INC | $27,501,000 | -2.5% | 851,409 | -0.0% | 2.40% | +10.0% |
| VNDA | VANDA PHARMACEUTICALS INC | $27,154,000 | -3.6% | 2,491,200 | 0.0% | 2.37% | +8.7% | |
| KPTI | KARYOPHARM THERAPEUTICS INC | $25,353,000 | -38.8% | 5,621,533 | 0.0% | 2.21% | -31.0% | |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $23,646,000 | -56.6% | 1,678,196 | -25.5% | 2.06% | -51.1% |
| ALKS | Sell | ALKERMES PLC | $17,975,000 | +1.4% | 603,400 | -10.4% | 1.57% | +14.4% |
| EHTH | Buy | EHEALTH INC | $15,438,000 | -24.7% | 1,654,693 | +0.1% | 1.35% | -15.1% |
| GOSS | Sell | GOSSAMER BIO INC | $14,653,000 | -3.9% | 1,750,651 | -0.3% | 1.28% | +8.3% |
| SNDX | SYNDAX PHARMACEUTICALS INC | $11,786,000 | +10.7% | 612,600 | 0.0% | 1.03% | +24.8% | |
| ALGN | ALIGN TECHNOLOGY INC | $10,486,000 | -45.7% | 44,305 | 0.0% | 0.91% | -38.8% | |
| EPZM | EPIZYME INC | $9,959,000 | +27.8% | 6,774,541 | 0.0% | 0.87% | +44.2% | |
| ANAB | ANAPTYSBIO INC | $8,750,000 | -17.9% | 431,024 | 0.0% | 0.76% | -7.4% | |
| CLVS | CLOVIS ONCOLOGY INC | $8,053,000 | -10.9% | 4,473,967 | 0.0% | 0.70% | +0.4% | |
| GRTS | GRITSTONE ONCOLOGY INC | $5,640,000 | -41.3% | 2,330,504 | 0.0% | 0.49% | -33.7% | |
| KZR | KEZAR LIFE SCIENCES INC | $5,427,000 | -50.2% | 656,200 | 0.0% | 0.47% | -43.9% | |
| CYTK | CYTOKINETICS INC | $4,389,000 | +6.7% | 111,717 | 0.0% | 0.38% | +20.4% | |
| TVTX | TRAVERE THERAPEUTICS INC | $4,024,000 | -6.0% | 166,069 | 0.0% | 0.35% | +6.0% | |
| MIRM | MIRUM PHARMACEUTICALS INC | $1,259,000 | -11.6% | 64,700 | 0.0% | 0.11% | 0.0% | |
| ALIMERA SCIENCES INC | $1,099,000 | -2.3% | 200,919 | 0.0% | 0.10% | +10.3% | ||
| NVAX | NOVAVAX INC | $643,000 | -30.2% | 12,500 | 0.0% | 0.06% | -21.1% | |
| ALDX | ALDEYRA THERAPEUTICS INC | $642,000 | -10.2% | 160,800 | 0.0% | 0.06% | +1.8% | |
| MGTA | MAGENTA THERAPEUTICS INC | $519,000 | -58.6% | 432,300 | 0.0% | 0.04% | -53.6% | |
| URGN | UROGEN PHARMA LTD | $201,000 | -5.6% | 24,500 | 0.0% | 0.02% | +12.5% | |
| TCMD | TACTILE SYSTEMS TECHNOLOGY I | $198,000 | -63.7% | 27,100 | 0.0% | 0.02% | -59.5% | |
| MARINUS PHARMACEUTICALS INC | $152,000 | -48.1% | 31,330 | 0.0% | 0.01% | -43.5% | ||
| KLDO | Exit | KALEIDO BIOSCIENCES INC | $0 | – | -309,692 | -100.0% | -0.04% | – |
| RIGL | Exit | RIGEL PHARMACEUTICALS INC | $0 | – | -652,395 | -100.0% | -0.15% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Biomarin Pharmaceuticals, Inc | 42 | Q3 2023 | 16.6% |
| UNITED THERAPEUTICS CORP DEL | 42 | Q3 2023 | 15.3% |
| INSMED INC | 42 | Q3 2023 | 14.1% |
| STAAR Surgical Company | 42 | Q3 2023 | 11.8% |
| AMICUS THERAPEUTICS INC | 42 | Q3 2023 | 12.1% |
| VANDA PHARMACEUTICALS INC | 42 | Q3 2023 | 5.8% |
| PROTHENA CORP PLC | 42 | Q3 2023 | 9.1% |
| CYTOKINETICS INC | 40 | Q3 2023 | 0.4% |
| ALIGN TECHNOLOGY INC | 39 | Q3 2023 | 2.5% |
| ABIOMED INC | 38 | Q3 2022 | 17.1% |
View Palo Alto Investors LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ALIMERA SCIENCES INCSold out | April 03, 2023 | 0 | 0.0% |
| Epizyme, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| INSMED Inc | February 14, 2023 | 5,871,291 | 4.3% |
| Vanda Pharmaceuticals Inc. | February 14, 2023 | 1,087,064 | 1.4% |
| ALIMERA SCIENCES INC | February 14, 2022 | 802,423 | 11.6% |
| Clovis Oncology, Inc. | February 14, 2022 | 3,997,826 | 3.1% |
| STAAR SURGICAL CO | February 14, 2022 | 1,140,511 | 2.4% |
| Aimmune Therapeutics, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| AMAG PHARMACEUTICALS, INC.Sold out | February 16, 2021 | 0 | 0.0% |
| ALIMERA SCIENCES INC | February 14, 2020 | 802,424 | 16.2% |
View Palo Alto Investors LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-04-03 |
| 4 | 2023-03-28 |
View Palo Alto Investors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.